Pharmacovigilance: a step towards the rational use of herbs and herbal medicines

被引：30

作者：

Balbino, Evelin E. ^{[1
]}

Dias, Murilo F. ^{[1
]}

机构：

[1] Agencia Nacl Vigilancia Sanit, SIA, Area Especial 57, BR-71205050 Brasilia, DF, Brazil

来源：

REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY | 2010年 / 20卷 / 06期

关键词：

Herbs; herbal medicines; pharmacovigilance; adverse events; Anvisa; CLINICAL-TRIAL; DOUBLE-BLIND; TOXICITY; EFFICACY;

D O I：

10.1590/S0102-695X2010005000031

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

"Pharmacovigilance: a step towards the rational use of herbs and herbal medicines". This article presents the evaluation of the notifications of adverse events related to medicinal plants and their derivatives (herbal medicines). Such evaluations were voluntarily run by the Brazilian Pharmacovigilance System, coordinated by the Brazilian Health Surveillance Agency (Anvisa), from January 1999 to March 2009. Pharmacovigilance involves the detection of adverse reactions that occur during or after the use of drugs, drug interactions, problems of quality, improper use and inefficacy. There is scarce scientific confirmation about efficacy and safety of herbal medicines, so the notification of adverse events provides of information, and promotes rational use.

引用

页码：992 / 1000

页数：9

共 29 条

[1]

Amorim Maria F. D., 2007, Rev. bras. farmacogn., V17, P448, DOI 10.1590/S0102-695X2007000300020

[2]

[Anonymous], 2004, WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems

[3]

[Anonymous], 1996, EXTRA PHARMACOPOEIA

[4]

Anvisa, 2009, NOV CONC FARM

[5] Pharmacovigilance of herbal medicines - A UK perspective [J].

Barnes, J .

DRUG SAFETY, 2003, 26 (12) :829-851

[6]

Brinker F, 2009, HERB CONTRAINDICATIO

[7] Phytotherapy and quality of herbal medicines [J].

Capasso, R ;

Izzo, AA ;

Pinto, L ;

Bifulco, T ;

Vitobello, C ;

Mascolo, N .

FITOTERAPIA, 2000, 71 :S58-S65

[8]

Congresso Nacional, 1973, LEI 5991 17 DEZ 1973

[9]

Council for International Organisations of Medical Sciences, 2001, CURR CHALL PHARM PRA

[10]

Cupp MJ, 1999, AM FAM PHYSICIAN, V59, P1239

← 1 2 3 →